CorrectQuestion: Which of the following best describes the mechanism of action of monoclonal antibodies used in targeted cancer therapy?

February 22, 2026

CorrectQuestion: Which of the Following Best Describes the Mechanism of Action of Monoclonal Antibodies in Targeted Cancer Therapy?

Introduction

In recent years, monoclonal antibodies (mAbs) have revolutionized cancer treatment by offering highly targeted, precision-based therapies. But with growing interest in this cutting-edge field, a common question arises: Which of the following best describes the mechanism of action of monoclonal antibodies used in targeted cancer therapy? Understanding this mechanism is key to appreciating how these therapies selectively attack cancer cells while minimizing damage to healthy tissues.

What Are Monoclonal Antibodies?

Monoclonal antibodies are laboratory-engineered proteins designed to mimic the immune system’s ability to recognize and bind to specific antigens. In oncology, they are designed to target unique proteins (antigens) expressed on the surface of cancer cells, allowing for enhanced specificity and precision in treatment.

Core Mechanisms of Action in Cancer Therapy

Monoclonal antibodies exert their anti-cancer effects through several distinct mechanisms, each tailored to disrupt cancer cell survival, growth, or immune evasion. Key mechanisms include:

1. Direct Targeting of Oncogenic Receptors

Many monoclonal antibodies bind directly to receptor tyrosine kinases (RTKs) overexpressed on cancer cells, such as HER2 in breast cancer (e.g., trastuzumab) or EGFR in lung and colorectal cancers. By blocking these receptors, mAbs prevent activation of signaling pathways that drive uncontrolled cell proliferation—a fundamental step in cancer development.

2. Antibody-Dependent Cellular Cytotoxicity (ADCC)

A major mechanism involves recruiting the body’s own immune system. Once the mAb binds to a tumor antigen, immune cells like natural killer (NK) cells recognize the antibody’s binding site via Fc receptors. This triggers NK cell-mediated destruction of the cancer cell through ADCC, effectively killing the targeted cell without direct engagement.

3. Complement-Dependent Cytotoxicity (CDC)

Some monoclonal antibodies activate the complement system, a cascade of proteins that forms pores in target cell membranes, leading to cell lysis. This pathway enhances tumor cell killing through innate immune mechanisms, particularly effective when the antibody binds in a way that allows complement protein assembly.

4. Delivery of Cytotoxic Payloads (Antibody-Drug Conjugates, ADCs)

Advanced mAbs are conjugated to potent chemotherapeutic drugs, radiometals, or toxins. Once internalized by cancer cells, these conjugates release their payload directly inside the malignancy, minimizing systemic toxicity and maximizing intracellular drug concentration. Examples include ado-trastuzumab emtansine (Kadcyla), which delivers a cytotoxic agent via HER2 binding.

5. Immune Checkpoint Modulation

A transformative class of monoclonal antibodies targets immune checkpoints—molecules that cancer cells exploit to evade immune detection. Agents like pembrolizumab (Keytruda) and nivolumab (Opdivo) block PD-1 or PD-L1, restoring T-cell activation and enabling immune-mediated tumor destruction.

6. Induction of Apoptosis and Cell Cycle Arrest

By binding specific surface antigens, monoclonal antibodies can initiate intracellular signaling cascades leading to apoptosis (programmed cell death) or halt cell cycle progression, effectively stopping tumor proliferation.

Why This Mechanism Matters

The specificity of monoclonal antibodies ensures that therapeutic effects are concentrated on malignancies expressing defined biomarkers, reducing harm to normal cells. Furthermore, their versatile mechanisms allow them to be used alone or in combination with chemotherapy, radiation, or other targeted agents—enhancing treatment efficacy and patient outcomes.

Conclusion

Correctly identifying the mechanism of action of monoclonal antibodies hinges on recognizing their multifaceted roles: direct receptor blockade, immune system recruitment through ADCC and CDC, targeted drug delivery via ADCs, and immune checkpoint inhibition. Understanding these pathways not only clarifies how mAbs work but also highlights their importance in modern, personalized oncology. As research progresses, emerging mechanisms and next-generation antibody designs continue to expand the frontiers of cancer therapy.

Key Takeaways:

Monoclonal antibodies target specific tumor antigens in cancer cells.
They work through receptor blockade, immune system activation (ADCC/CDC), direct cytotoxic delivery, and immune checkpoint inhibition.
High specificity reduces off-target effects and enhances treatment precision.
Ongoing innovations improve efficacy, especially in combination regimens.

Frequently Asked Questions (FAQ)

Can monoclonal antibodies kill cancer cells without immune system involvement? Yes—some mAbs directly induce apoptosis or trigger cell cycle arrest.
Do all monoclonal antibodies work the same way? No—their mechanisms vary based on design, target, and payload.
What determines which mechanism dominates in a specific mAb? The target antigen, the antibody’s structure (e.g., IgG subclass, Fc region), and how it’s engineered for digestion or conjugation.

References

National Cancer Institute (NCI) – Monoclonal Antibodies
FDA Drug Approvals and Labeling for Monoclonal Antibodies in Oncology
peer-reviewed journals: Nature Reviews Cancer, The Lancet Oncology

Optimized for SEO: Keywords: Monoclonal antibodies cancer treatment, mechanism of action monoclonal antibodies, targeted cancer therapy mAbs, antibody drug conjugates, immune checkpoint inhibitors summary Ideal for patients, oncologists, and healthcare professionals seeking clear, accurate insights into how targeted biologic therapies work in oncology.

Stay informed. Innovate confidently. Understand monoclonal antibodies—your key to precision medicine.